Local cerebral metabolic effects of L-dopa therapy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys
The quantitative 2-deoxy(/sup 14/C) glucose autoradiographic method was used to map the distribution of alterations in local cerebral glucose utilization that accompanies clinically effective chronic L-dopa therapy of rhesus monkeys made parkinsonian by the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). This pattern of changes was compared to the effects of a similar treatment regimen in normal monkeys. L-Dopa was administered orally to normal and parkinsonian monkeys 3 times daily for 60-120 days prior to measurement of local cerebral glucose utilization. In parkinsonian monkeys treated with L-dopa, signs and symptoms of parkinsonism were controlled or suppressed, and widespread increases in glucose utilization were seen throughout the brain. Cerebral metabolic activity was increased both in areas rich in dopaminergic receptors, such as the caudate and putamen, and in nondopaminergic areas involved in motor functions. In many structures the rates of glucose utilization in L-dopa-treated parkinsonian monkeys were increased to levels that far exceeded rates measured in normal monkeys. In sharp contrast, similar treatment with L-dopa in normal monkeys had little if any effect on local cerebral glucose utilization. L-Dopa, then, appears to have an action in animals with selective lesions of the substantia nigra pars compacta produced by MPTP that is distinctly different from its effects in the normal monkey.
- Research Organization:
- National Institutes of Health, Bethesda, MD (USA)
- OSTI ID:
- 5295769
- Journal Information:
- Proc. Natl. Acad. Sci. U.S.A.; (United States), Vol. 84:16
- Country of Publication:
- United States
- Language:
- English
Similar Records
Distribution of 1-methyl-4-phneyl-1,2,3,6-tetrahydropyridine in experimental animals studied by positron emission tomography and whole body autoradiography
6-( sup 18 F)fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures
Related Subjects
CARBON 14 COMPOUNDS
METABOLISM
CEREBRUM
AUTORADIOGRAPHY
DOPA
BIOLOGICAL EFFECTS
BEHAVIOR
GLUCOSE
MONKEYS
NERVOUS SYSTEM DISEASES
PHYSIOLOGY
ALDEHYDES
AMINO ACIDS
ANIMALS
AUTONOMIC NERVOUS SYSTEM AGENTS
BODY
BRAIN
CARBOHYDRATES
CARBOXYLIC ACIDS
CENTRAL NERVOUS SYSTEM
DISEASES
DRUGS
HEXOSES
HYDROXY ACIDS
LABELLED COMPOUNDS
MAMMALS
MONOSACCHARIDES
NERVOUS SYSTEM
NEUROREGULATORS
ORGANIC ACIDS
ORGANIC COMPOUNDS
ORGANS
PRIMATES
SACCHARIDES
VERTEBRATES
550501* - Metabolism- Tracer Techniques
550201 - Biochemistry- Tracer Techniques